Brief: PCI Biotech Holding Q3 Operating Loss Narrows To NOK 8.4 Million
Nov 13 (Reuters) - PCI Biotech Holding ASA PCIB.OL :
* FOCUS IS NOW TO BRING FIMACHEM TO MARKET FOR TREATMENT OF
INOPERABLE BILE DUCT CANCER
* Q3 OPERATING LOSS NOK 8.4 MILLION VERSUS LOSS NOK 10.5
MILLION
YEAR AGO
Source text for Eikon: ID:nGNEF5XcZ
Further company coverage: PCIB.OL
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 587720920;))
Recent news on PCI Biotech Holding ASA
See all newsBrief: Euronext Oslo Børs To Delist PCI Biotech Holding Shares
Brief: Euronext Oslo Børs Gets Application From PCI Biotech Holding For Delisting
Brief: PCI Biotech Holding Board Proposes Dissolution, Delisting
Brief: Oslo Bors: PCI Biotech Holding Is Placed In Recovery Box
Brief: PCI Biotech Says Co Initiates Process To Evaluate Opportunity For Structured Wind-Up Process